Notably, patients who were aged < 60 years, with clinical stage IV, co‐occurring EGFR and TP53 mutations, brain metastases, ECOG PS ≤ 1, baseline CEA < 5 μg/L, and a tumor diameter > 5 mm achieved DCRs of up to 100%. This evidence concerns the gene CEACAM5 and neoplasm.